Foyston Gordon & Payne Inc lessened its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 63.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,724 shares of the company's stock after selling 107,481 shares during the quarter. Foyston Gordon & Payne Inc's holdings in Kenvue were worth $1,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of Kenvue in the fourth quarter valued at $521,348,000. Franklin Resources Inc. raised its holdings in shares of Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock valued at $2,085,070,000 after buying an additional 10,682,003 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Kenvue by 3.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after purchasing an additional 8,211,748 shares during the period. Finally, Boston Partners raised its holdings in Kenvue by 36.9% during the 4th quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after buying an additional 6,366,097 shares during the last quarter. Institutional investors own 97.64% of the company's stock.
Kenvue Price Performance
Kenvue stock traded up $0.53 during midday trading on Thursday, reaching $23.73. 9,841,843 shares of the stock traded hands, compared to its average volume of 17,045,410. The stock has a market cap of $45.52 billion, a P/E ratio of 44.75, a PEG ratio of 2.62 and a beta of 1.02. The stock's fifty day moving average is $23.15 and its 200-day moving average is $22.58. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter last year, the business posted $0.28 earnings per share. The firm's revenue was down 3.9% on a year-over-year basis. As a group, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is currently 149.09%.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the stock. Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price on the stock. UBS Group raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Citigroup raised their price objective on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a report on Friday, May 9th. Finally, Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $25.33.
Check Out Our Latest Research Report on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
